Dermatology Times Newsletter

To view this email as a web page, click here.

Clinical Considerations for Derm NPs and PAs

This month’s highlights center prescribing spironolactone for patients with hormonal acne, using biologics to treat hidradenitis suppurtiva, and questioning the conventional wisdom of the progression rate and risk of cutaneous lupus converting to systemic disease. Read my comments below, and the stories for further insights!. Read my takeaways and the full stories below!
— Joe Gorelick

CLINICAL CONSIDERATIONS

Spironolactone for hormonal acne

Do you prescribe Spironolactone for the treatment of hormonal acne? What is your starting dosage? Spironolactone has proven to be an effective and safe treatment option for hormonal acne. In fact, for healthy patients laboratory potassium monitoring is often not performed.

Read more to familiarize yourself with these and other updates in pediatric dermatology.

Biologics offer promise for hidradenitis suppurativa treatment

Hidradenitis Supperativa (HS) is a devastating disease for patients and is difficult to treat effectively for health care providers. Adalibumab is the only approved biologic indicated for the treatment of HS in the US and, as Dr. Kerdel discusses, represents a novel therapeutic option for the HS patient population. We now appreciate that the likely etiology of HS is inflammatory vs infectious so targeting the inflammatory cascade via biologic therapy has shown efficacy. Dr. Kerdel also discusses additional specific inflammatory pathways that may be targeted with other biologic agents such as secukinumab, infliximab, and anakinra to treat HS. These agents are currently under investigation and may result in much needed additional approved therapies for HS.

Learn more.

Skin lupus can progress more rapidly than previously thought

This is a fascinating article that may challenge the conventional thought with regard to the progression rate and risk of cutaneous lupus (discoid lupus erythematosus/DLE) converting to systemic disease. Dermatology offices will often represent the first line of defense for these patients as they present with skin lesions and the diagnosis of DLE is confirmed with biopsy. Dr. Merola specifically focused on the risk of progression to systemic disease among patients with (DLE) suggesting systemic disease can develop within one to two years of initial diagnosis. This patient population will need to be managed collaboratively with our rheumatology colleagues to ensure appropriate counseling and management.

Do you refer all patients diagnosed with DLE for a Rheumatology evaluation?

JOB OPPORTUNITIES

AZ - Integrated Dermatology

CO - Dermatology Specialists of Boulder

CO - Leavitt Management Group

CT - Integrated Dermatology

FL - Integrated Dermatology

FL - Leavitt Management Group

FL - Associates in Dermatology

GA - Leavitt Management Group

IL - Integrated Dermatology

IA - Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

MI - Leavitt Management Group

MI - Integrated Dermatology

MT - Billings Clinic

National - Integrated Dermatology

NC - Integrated Dermatology

NJ - Integrated Dermatology

NV - Integrated Dermatology

NY - Integrated Dermatology

OR - Cynthia Dreyer MD

PA - Milton S Hershey Medical Center

PA - Leavitt Management Group

TN - Integrated Dermatology

RI - Leavitt Management Group

VA - Integrated Dermatology

WA - Integrated Dermatology

WY - Leavitt Management Group

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT